← Leaderboards
Prakash Radhakrishnan
University Of Nebraska Medical Center
$1,968,572
Attributed
$2,244,342
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $551.5K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,244,342 · 2
By mechanism
R01$2,244,342 · 2
Top collaborators
- Richard D Cummings2 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Michael A Hollingsworth$34,707,253
- Maneesh Jain$6,905,007
- Moorthy P. Ponnusamy$2,721,536
- Rebekah L. Gundry$10,781,663
- Ravi Salgia$9,622,551
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroMolecularGemcitabineHypermethylationMalignant - DescriptorMediatingCytokineEngineeringGlycoproteinsGrowth FactorIn VivoLigandsMalignant Neoplasm Of PancreasAutopsyAnimalsBiologicalDiagnosisDisease ProgressionAdenocarcinomaGenetic EngineeringCancer CellGrowthCombined Modality TherapyMolecular Chaperones
Grant awards (7)
Targeting Disease Specific Tn Antigen in Pancreatic Cancer$433,763
R01 · FY2025 · CA · contact PI
Targeting Disease Specific Tn Antigen in Pancreatic Cancer$117,777
R01 · FY2025 · CA · contact PI
MUC16 in Pancreatic Cancer Progression and Metastasis$338,280
R01 · FY2021 · CA · contact PI
MUC16 in Pancreatic Cancer Progression and Metastasis$338,280
R01 · FY2020 · CA · contact PI
MUC16 in Pancreatic Cancer Progression and Metastasis$328,130
R01 · FY2019 · CA · contact PI
MUC16 in Pancreatic Cancer Progression and Metastasis$342,147
R01 · FY2018 · CA · contact PI
MUC16 in Pancreatic Cancer Progression and Metastasis$345,965
R01 · FY2017 · CA · contact PI